循环游离线粒体DNA与突发性感音神经性听力损失的关联
这项观察性前瞻性研究纳入50例突发性感音神经性听力损失患者和30名健康对照,检测血浆循环游离线粒体DNA水平。患者水平显著高于对照,且治疗前水平较高者恢复更好,并与听力增益和恢复百分比正相关。发病至治疗不足7天及较高循环游离线粒体DNA水平为良好恢复的独立预测因素。
要点
- 突发性感音神经性听力损失患者血浆循环游离线粒体DNA水平显著高于健康对照。
- 治疗前循环游离线粒体DNA水平较高者恢复更好,且与听力增益和恢复百分比正相关。
- 发病至治疗不足7天及较高循环游离线粒体DNA水平为良好恢复的独立预测因素。
核心结论
- 突发性感音神经性听力损失患者血浆循环游离线粒体DNA水平升高,且与类固醇治疗后更好的治疗结局显著相关。
- 这些发现提示循环游离线粒体DNA水平可能作为突发性感音神经性听力损失治疗结局的预测生物标志物,为个体化治疗策略开辟道路。
研究设计与样本
- 观察性前瞻性研究,在三级学术医疗中心开展。
- 纳入80名受试者,包括50例突发性感音神经性听力损失患者和30名健康对照。
- 在类固醇治疗前的早晨采集患者血浆样本,同时采集健康对照样本。
- 采用定量聚合酶链反应测定循环游离线粒体DNA水平,以每毫升对数拷贝数表示。
- 采用听力增益、恢复百分比和Siegel标准评估治疗结局。
主要发现
- 患者平均(标准差)血浆循环游离线粒体DNA水平为8.1(0.35),显著高于对照的7.78(0.65)(95%CI:0.097-0.542)。
- 恢复良好者治疗前循环游离线粒体DNA水平显著高于恢复不良者(平均[标准差]评分:8.29[0.34] vs 8.02[0.33];95%CI:0.04-0.48)。
- 循环游离线粒体DNA水平与听力增益正相关(r=0.486,95%CI:0.227-0.663),与恢复百分比正相关(r=0.361,95%CI:0.103-0.574)。
- 多因素分析显示,发病至治疗不足7天(比值比[OR]:7.389,95%CI:1.324-41.239)和较高循环游离线粒体DNA水平(OR:24.634,95%CI:1.878-323.163)为良好恢复的独立预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association of circulating cell-free mitochondrial DNA (ccf-mtDNA) levels with the severity and treatment outcomes of sudden sensorineural hearing loss (SSNHL). STUDY DESIGN: Observational prospective study. SETTING: Tertiary academic medical center. METHODS: Plasma samples were collected from patients diagnosed with SSNHL in the morning before steroid treatment, as well as from healthy controls. A quantitative polymerase chain reaction was used to measure ccf-mtDNA levels, expressed as log copy numbers per milliliter. Treatment outcomes were evaluated using hearing gain, percentage of recovery, and Siegel's criteria. RESULTS: The study included 80 subjects, including 50 patients and 30 healthy controls. The mean (SD) plasma ccf-mtDNA level was 8.1 (0.35), which was significantly higher than 7.78 (0.65) controls (95% CI: 0.097-0.542). Patients with good recovery exhibited significantly higher pretreatment ccf-mtDNA levels compared to those with poor recovery (mean [SD] score: 8.29 [0.34] vs 8.02 [0.33]; 95% CI: 0.04-0.48). Ccf-mtDNA levels were positively associated with hearing gain (r = 0.486, 95% CI: 0.227-0.663) and percentage of recovery (r = 0.361, 95% CI: 0.103-0.574). Multivariate analyses revealed that less than 7 days from onset of hearing loss to treatment (odds ratio [OR]: 7.389, 95% CI: 1.324-41.239) and higher ccf-mtDNA levels (OR: 24.634, 95% CI: 1.878-323.163) were independent predictors for good recovery. CONCLUSION: Plasma ccf-mtDNA levels were elevated in patients with SSNHL and were significantly associated with better treatment outcomes following steroid therapy. These findings suggest that ccf-mtDNA levels may serve as a predictive biomarker for SSNHL treatment outcomes, paving the way for personalized therapeutic strategies.
引用
- Yang CH, Yang MY, Lin WC, et al. Association of Circulating Cell-Free Mitochondrial DNA With Sudden Sensorineural Hearing Loss. Otolaryngol Head Neck Surg. 2025. PMID: 40125726. doi:10.1002/ohn.1238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。